Weight management · Phase 2
Retatrutide: phase 2 obesity study
What was tested?
Retatrutide versus placebo in adults with overweight or obesity. ↗
Registered primary question: Percentage change in body weight at week 24. ↗
What the reviewed report found
Journal year 2023 · Article summary reviewed 2026-09-15
At 48 weeks, reported mean body-weight change ranged from -8.7% to -24.2% across retatrutide groups, compared with -2.1% for placebo. Gastrointestinal events were the most common adverse events, and heart-rate increases peaked at 24 weeks before declining.↗
Keep in context: The often-cited 48-week weight results are secondary outcomes; the primary endpoint was measured at week 24. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 338 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years to 75 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2023-09-13; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Phase 2 obesity trial
- Design in the report
- A double-blind, randomized, placebo-controlled Phase 2 trial followed participants for 48 weeks and assessed body-weight change and safety.↗
- Participants in the report
- The trial enrolled 338 adults with obesity, or overweight plus at least one weight-related condition.↗
- Limitations
- This was a sponsor-funded Phase 2 trial with 48-week follow-up; it was not a long-term cardiovascular-outcomes or rare-harms study.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight ↗
Protocol identifier: 18122. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 02ff67711c363c67a5a141a183cc3f734d4702e1b3877385214a39abc81b20b4.
PMID 37366315
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 37366315. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 167232d6f5d1818faabbc3d98c283b2ffad85563d5e10720f8e23347bba1ad1b.